Holen Sie sich die Stockscreener-App
2.93
2.45%
0.07
Handel nachbörslich:
2.90
-0.03
-1.02%
Schlusskurs vom Vortag:
$2.86
Offen:
$2.9
24-Stunden-Volumen:
283.11K
Relative Volume:
1.01
Marktkapitalisierung:
$89.89M
Einnahmen:
$875.70K
Nettoeinkommen (Verlust:
$-39.57M
KGV:
-2.1828
EPS:
-1.3423
Netto-Cashflow:
$-33.65M
1W Leistung:
-1.35%
1M Leistung:
+23.11%
6M Leistung:
+2.81%
1J Leistung:
-13.57%
1-Tages-Spanne:
$2.84
$3.0499
1-Wochen-Bereich:
$2.71
$3.0499
52-Wochen-Spanne:
$1.90
$3.79
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Firmenname
Vistagen Therapeutics Inc
Sektor
Branche
Telefon
650-577-3600
Adresse
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie VTGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
2.93 | 87.75M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-07 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-07 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-07-22 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-02-18 | Eingeleitet | Jefferies | Buy |
| 2021-01-04 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | Eingeleitet | Maxim Group | Buy |
| 2018-02-08 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-03-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Vistagen Therapeutics Inc Aktie (VTGN) Neueste Nachrichten
Vistagen (VTGN) Q1 R&D Expense Jumps 54% - AOL.com
Vistagen Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2026 Earnings Call Transcript - Insider Monkey
Is Vistagen Therapeutics Inc. stock a good dividend stockGame-Changing Investment Alerts - thegnnews.com
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates - MSN
VistaGen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Meets Estimates - MarketBeat
Vistagen signals Q4 2025 Phase III data readout for fasedienol as pipeline advances - MSN
Vistagen Therapeutics (VTGN) Advances Phase III Trials for Social Anxiety Treatment - GuruFocus
Vistagen Therapeutics Inc (VTGN) Q1 2026 Earnings Call Highlights: Advancing Key Trials Amid ... - Yahoo Finance
Vistagen Therapeutics Inc (VTGN) Q1 2026 Earnings Call Highlights: Advancing Key Trials Amid Financial Challenges - GuruFocus
Earnings call transcript: VistaGen Therapeutics’ Q1 2025 sees increased R&D costs - Investing.com Nigeria
Earnings call transcript: VistaGen Therapeutics’ Q1 2025 sees increased R&D costs By Investing.com - Investing.com South Africa
Vistagen 2026 Q1 Earnings Widened Losses Despite Surging Revenue - AInvest
Vistagen Therapeutics Reports Progress in Clinical Trials - TipRanks
Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update - BioSpace
Aon Appoints Jo Ann Jenkins to Board of Directors - AInvest
Vistagen Reports Q1 Earnings, Advances Key Programs Across Pipeline - AInvest
Vistagen Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
VistaGen Therapeutics (VTGN): Clinical Catalysts and Financial Pressures—Is the Biopharma Still Worth the Gamble? - AInvest
VistaGen Therapeutics Inc Q1 Sales Increase - Nasdaq
VistaGen Reports Q1 2026 Financial Results and Update - TipRanks
Vistagen reports Q1 EPS (47c), consensus (44c) - TipRanks
VistaGen Therapeutics: Balancing Burn with Biotech Breakthroughs in a High-Stakes Race - AInvest
Vistagen Therapeutics, Inc. SEC 10-Q Report - TradingView
Biopharmaceutical firm VistaGen Q1 net loss widens - MarketScreener
Market reaction to Vistagen Therapeutics Inc.’s recent newsValue Investing Checklist with Entry Signals - Newser
Insights Ahead: VistaGen Therapeutics's Quarterly Earnings - 富途牛牛
What makes Vistagen Therapeutics Inc. stock price move sharplyTechnical Chart Summary for Momentum Stocks - Newser
How to track smart money flows in Vistagen Therapeutics Inc.Stock Portfolio Risk and Return Analysis - Newser
Will Vistagen Therapeutics Inc. see short term momentumBuy Zone Strategy with Pattern Recognition - Newser
Is Vistagen Therapeutics Inc. stock a good hedge against inflationDaily Stock Movement Forecast with Accuracy - Newser
Using R and stats models for Vistagen Therapeutics Inc. forecastingMachine Learning Stock Movement Detector - Newser
Using Python tools to backtest Vistagen Therapeutics Inc. strategiesShort Term Gain Strategy with AI Logic - Newser
VistaGen Therapeutics (VTGN) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Vistagen VTGN 2026Q1 Earnings Preview Upside Potential on Neuroscience Pipeline Progress - AInvest
Evaluating Vistagen Therapeutics Inc. with trendline analysisFree Real-Time Analysis With Entry Targets - Newser
Real Time Chart Alerts Flash Bullish on Vistagen Therapeutics Inc.Entry Alert With Low Drawdown Strategy Noted - beatles.ru
Intraday pattern recognizer results for Vistagen Therapeutics Inc.Daily Upside Movement Prediction With Data - Newser
What are analysts’ price targets for Vistagen Therapeutics Inc. in the next 12 monthsOutstanding growth strategies - Jammu Links News
Is it the right time to buy Vistagen Therapeutics Inc. stockRapidly expanding wealth - Jammu Links News
Does Vistagen Therapeutics Inc. stock perform well during market downturnsFree Consultation - Jammu Links News
Should I hold or sell Vistagen Therapeutics Inc. stock in 2025Free Stock Market Trend Analysis - Jammu Links News
Is Vistagen Therapeutics Inc. a growth stock or a value stockConsistently profitable trades - Jammu Links News
What analysts say about Vistagen Therapeutics Inc. stockGet daily updates on promising stocks - Jammu Links News
How many analysts rate Vistagen Therapeutics Inc. as a “Buy”Outstanding capital returns - Jammu Links News
How volatile is Vistagen Therapeutics Inc. stock compared to the marketDiscover market opportunities with expert help - Jammu Links News
When is Vistagen Therapeutics Inc. stock expected to show significant growthMaximize your gains with expert trading tips - Jammu Links News
What institutional investors are buying Vistagen Therapeutics Inc. stockFree Stock Market Knowledge Sharing - jammulinksnews.com
What are the technical indicators suggesting about Vistagen Therapeutics Inc.Build wealth with high-performing stocks - Jammu Links News
Published on: 2025-08-03 02:29:23 - Jammu Links News
Vistagen Therapeutics Inc. Stock Analysis and ForecastFree Popular Stock Recommendations - Jammu Links News
Finanzdaten der Vistagen Therapeutics Inc-Aktie (VTGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):